RE: Biopharm International8 Nov 2021 06:40
Hi Hall123, I’ve popped over from the other board to see what’s on here. I thought our chat board was quiet!
Still while I’m here I’ll add based on the operations update released on 14 Sept where in vitro results announced a positive platform for the commencement of the in vivo work beginning then which was expected to last six to eight weeks with an additional two to three weeks for analysis. If they started when that RNS went out the results should be in an RNS very soon.
As I also posted on the other board Nigel Theobald, Chief Executive Officer of the Company, commented at the time:
"The Board is very pleased with these initial in vitro results from the new SARS-COV-2 plasmid which confirms Nuvec® is capable of producing results in this area and demonstrate a material improvement on previous results with an earlier plasmid.
"We are very excited to commence the in vivo work using this SARS-COV-2 plasmid alongside the MTA (Material Transfer Agreement) work already in place with a potential partner in this area. The aim of the study is to demonstrate the potential of using Nuvec® to develop plasmid DNA vaccines using much lower doses than those already approved or are in development and also not requiring refrigeration."
GLA on invested this board - I’ll head back now ;-)